|
Product |
Manufacturer |
Description |
Comments |
Status |
Phase 3 Clinical Trials |
|
|
Rituximab |
Genentech/Biogen Idec |
anti-CD20, induces B-cell depletion; delivered via IV for B-cell non-Hodgkin's lymphoma
in 100 mg or 500 mg single-use vials; 1000 mg IV on days 1 and 15 for Hauser et
al trial for RRMS |
Promising for RRMS (HERMES
Phase 2); PPMS Phase 3 results due H1:08 (has 439
patients enrolled, primary endpoint is time to progression over 96 weeks) |
Phase 2/3 |
1. OLYMPUS - A Study
to Evaluate the Safety and Efficacy of Rituximab in Adults With
Primary Progressive Multiple Sclerosis, 2004-2008 (NCT00087529)
(Primary endpoint is time-to-disease progression measured by EDSS at 96 weeks) |
|
Ocrelizumab
|
Genentech
|
2nd generation anti-CD20 |
Legal issues with Biogen may be holding things up |
Phase 3 |
none found for M.S. |
|
|
Campath (Alemtuzamab) |
Genzyme/Bayer |
anti-CD52, induces rapid and prolonged depletion of peripheral T-cells |
Needs to prove monthly monitoring can protect against ITP (immune thrombocytopenia
purpura)
|
Phase 3
|
1.
CARE-MS I - Comparison
of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One -
no previous treatment, 2007-2011 (NCT00530348) 2. CARE MS II - Comparison of Alemtuzumab and Rebif
Efficacy in Multiple Sclerosis, Study Two - previous DMD treatment, 2007-2011 (NCT00548405) |
|
|
ABT-874 |
Abbot/CAT |
neutralizes interleukin-12 |
|
Phase 2 |
1.
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects
With Multiple Sclerosis (MS), 2004-2006 (NCT00086671)
Phase 2 completed |
|
|
MLN1202 |
Millennium |
blocks CCR2 chemokine receptors and prevents infiltration of immunce cells into
inflammatory sites |
|
|
none found for M.S. |
|
|
Zenapax (daclizumab) |
Protein Design Labs/Biogen Idec |
anti-CD25 |
|
Phase 2 |
1. Zenapax (Daclizumab)
to Treat Relapsing Remitting Multiple Sclerosis, Phase 2 (NCT00071838) 2. Zenapax to Treat Multiple
Sclerosis, Phase
2 (NCT00001934)
3. Safety and Efficacy Study of Daclizumab
HYP to Treat Relapsing-Remitting Multiple Sclerosis,
Phase 2 (NCT00390221) |
|
CNTO-1275
|
Centocor/Medarex |
anti-IL-12 |
|
Phase 2 |
1.
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis,
2004-2006 (NCT00207727)
Phase 2 completed
|
|